SKIN — SkinHealth Systems Inc.

Summary of The Beauty Health Company (SKIN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $82.4 million, down 1.3% year-over-year, showing improvement from a double-digit decline in Q3.
• Consumables Revenue: Increased to $57.7 million (up 1.7% year-over-year).
• Device Revenue: $24.7 million, down 7.9% year-over-year but improved from Q3.
• Adjusted Gross Margin: Expanded to 67.4%, with GAAP gross margin at 64.4%.
• Adjusted EBITDA: $15 million for Q4, up from $9 million in the prior year; full-year adjusted EBITDA was $45.1 million, significantly up from $12.3 million in 2024.
• Net Loss: Improved to $8.1 million from $10.3 million in the prior year.
• Installed Base: Over 36,000 systems globally, with 1,032 devices placed in Q4.

2. Strategic Updates and Business Highlights

• Market Position: The company is focusing on transitioning from a device placement model to a utilization-driven model to enhance revenue from existing installations.
• Sales Strategy: Implementing a value-based selling model to demonstrate the economic benefits of HydraFacial treatments to providers.
• Marketing Focus: Refining marketing strategies to emphasize clinical-grade skin health and expanding consumer demand generation.
• Innovation: Plans for a next-generation HydraFacial system targeting a 2028 launch, aimed at enhancing provider value and market share.
• Operational Improvements: Strengthened balance sheet and cost structure, with a focus on expense discipline and operational rigor.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $285 million and $305 million, reflecting a modest decline compared to 2025.
• Adjusted EBITDA Guidance: Projected between $35 million and $45 million for 2026.
• Q1 2026 Expectations: Revenue forecast of $63 million to $68 million, with positive adjusted EBITDA of $3.5 million to $5.5 million.
• Long-term Outlook: Anticipate returning to growth in 2027 as operational initiatives take hold.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Overall revenue is expected to decline in 2026, primarily due to ongoing macroeconomic pressures and a challenging capital equipment market.
• Churn Rate: Although improved in Q4, churn was higher than usual for 2025, particularly among smaller accounts lacking dedicated business development support.
• Market Pressures: The aesthetics market is experiencing pressure from tighter credit conditions affecting capital spending decisions.
• Competitive Landscape: Increased competition has lengthened the device sales cycle, affecting sales performance.

5. Notable Q&A Insights

• Churn Management: The company aims to stabilize churn rates through better support for smaller accounts and restructuring sales teams.
• Consumer Trends: Consumers are prioritizing clinically proven results and are more selective in their treatment choices, which aligns well with HydraFacial's offerings.
• Pricing Strategy: A recent price increase on consumables was well-received, with no significant pushback noted.
• Operational Efficiencies: The company is working on centralizing operations to reduce costs while investing in R&D for future growth.

Overall, The Beauty Health Company is focused on stabilizing its operations and preparing for future growth, despite facing challenges in revenue and market conditions. The strategic shift towards enhancing utilization of its installed base and disciplined operational execution is expected to position the company for recovery and growth in the coming years.